Abstract：Objective To explore the prognostic benefits and influencing factors of neoadjuvant chemotherapy (NACT) combined with
interval debulking surgery (IDS) in patients with advanced ovarian epithelial cell carcinoma. Methods Clinical data of 102 patients
with advanced ovarian epithelial cell carcinoma who underwent primary debulking surgery (PDS) and NACT combined with IDS in
our hospital from January 2015 to January 2019 were analyzed retrospectively. Inpatient data were collected and survival follow-up
was performed. Univariate, multivariate and survival curve analysis were performed on the factors affecting the prognosis of patients.
Results The median progression-free survival (PFS) of the PDS group was 15.2 months, and that of the NACT+IDS
group was 9.1 months, the difference in PFS between the two groups was statistically significant (P<0.05). Univariate analysis and
Cox multivariate analysis showed that the time of postoperative chemotherapy initiation, postoperative residual lesion size and body
mass index were independent influencing factors of PFS in the NACT+IDS group (P<0.05). Postoperative residual lesion size, pre-
IDS serum carbohydrate antigen 125 (CA125) level and surgical pathological stage were independent factors influencing overall
survival (OS) of patients in NACT+IDS group (P<0.05). There were statistically significant differences in the size of postoperative
residual lesions, the normal level of serum CA125 before IDS and the median OS between stage Ⅲc and stage Ⅳ in NACT+IDS
group (P<0.05). The time of postoperative chemotherapy initiation after IDS treatment was an independent influencing factor for
PFS in the NACT+IDS group, and the normal level of serum CA125 before IDS was an independent influencing factor for OS in the
NACT+IDS group (P<0.05). Conclusion Postoperative residual lesion size, pre-IDS serum CA125 level and surgical pathological
stage in patients with NACT+IDS are independent influencing factors of PFS and OS in patients with NACT+IDS group. The pre-IDS
serum CA125 level is detected and reduced to normal level, and perioperative management of IDS is strengthened in patients with
NACT+IDS. It can improve the prognosis of patients with advanced ovarian epithelial cell carcinoma.
沈需，吕卫琴，尚云，马睿，柴馨婷. MACT联合IDS治疗晚期卵巢上皮
细胞癌的预后获益及影响因素分析[J]. 中国医疗设备, 2023, 38(3): 131-137.
SHEN Xu, LV Weiqin, SHANG Yun, MA Rui, CHAI Xinting. Analysis of Prognostic Benefit and Influencing Factors of NACT Combined with IDS in the
Treatment of Advanced Ovarian Epithelial Cell Carcinoma. China Medical Devices, 2023, 38(3): 131-137.
